Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

48.18 -0.11 (-0.23%)
Streaming Delayed Price Updated: 9:38 AM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
42 43 Next >
News headline image
Forget the Fed. These 3 Stocks Will Soar No Matter What ↗
The Fed's actions will have little impact on some stocks. Here are three excellent stocks that are likely to be unaffected by the Fed. 
Via InvestorPlace
Topics Economy
News headline image
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week ↗
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
News headline image
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle ↗
Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent... 
Via Benzinga
Topics Intellectual Property Lawsuit
News headline image
What's Going On With Pfizer Stock On Thursday? ↗
GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying high-stakes legal battles in the U.S. 
Via Benzinga
Topics Intellectual Property
News headline image
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges ↗
Discover the impact of Brexit on UK drug shortages. Insights from a recent Nuffield Trust study reveal a doubling in shortages since 2020. Learn about challenges in medicine supplies, regulatory... 
Via Benzinga
Topics Brexit
News headline image
Peering Into GSK's Recent Short Interest ↗
 
Via Benzinga
News headline image
Once Valued At Billions, 23andMe's CEO Considers Privatization To Secure Company's Future ↗
Anne Wojcicki, CEO of 23andMe mulls taking the genetics company private amid market challenges. With declining revenue and a focus shift to drug development, the move seeks funding for potential... 
Via Benzinga
News headline image
GSK Says Its Blockbuster Shingles Vaccine Shows High Efficacy Even After 10 Years ↗
Lasting protection against shingles for adults over 50 with GSK's RZV vaccine. New data from ZOSTER-049 trial reveals over a decade of high efficacy. Plus, GSK's oral antibiotic, gepotidacin, shows... 
Via Benzinga
News headline image
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields ↗
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
News headline image
Down 75%. Is Agenus Stock a Buy on the Dip? ↗
Wall Street analysts who watch the cancer drug developer closely think it could rocket higher. 
Via The Motley Fool
News headline image
CureVac, GS Partner Release Data On Influenza Vaccine Study ↗
CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen coverage with acceptable safety. Positive findings against influenza A... 
Via Benzinga
News headline image
In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster ↗
Sanofi reaches a settlement in principle for about 4,000 Zantac lawsuits in the US, excluding Delaware, regarding alleged cancer risks linked to NDMA. Financial terms remain undisclosed. 
Via Benzinga
Topics Lawsuit
News headline image
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia 
Via MarketBeat
News headline image
2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now? ↗
These stocks could rocket higher, but they also present significant risks. 
Via The Motley Fool
News headline image
Russell 2000 Index Best And Worst Performing Stocks Of 2024 ↗
The Russell 2000 index continued to underperform the Dow Jones and Nasdaq 100 indices in the first quarter of 2024. 
Via Talk Markets
Topics Stocks
News headline image
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback ↗
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
News headline image
Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead? ↗
Several well-regarded funds run by famous billionaire investors bought shares of 23andMe during the last three months of 2023. 
Via The Motley Fool
News headline image
Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month ↗
GSK caps asthma and COPD medicine costs at $35/month, effective Jan 1, 2025. Includes Advair, Breo, Ventolin. Follows AstraZeneca's suit for their respiratory medicines. Sanders applauds move amid... 
Via Benzinga
News headline image
GSK Reveals New Phase 3 Data For Jemperli Combo Therapy To Support Expanded Use Approval For Wider Endometrial Cancer ↗
Latest advancements in endometrial cancer treatment with GSK's Jemperli (dostarlimab)! Explore promising overall survival and progression-free survival results from the RUBY trial, paving the way for... 
Via Benzinga
News headline image
Pfizer To Cut Stake In Sensodyne Toothpaste-Maker Haleon, Potentially Worth £2B ↗
Pfizer to reduce stake in Haleon to approximately 24% following earlier divestment announcement. Offer price per share to be revealed post book-building process by Haleon. 
Via Benzinga
News headline image
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
From GSK plc
Via Business Wire
News headline image
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio ↗
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses. 
Via InvestorPlace
News headline image
Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead ↗
Don't fall for the siren song of penny stocks. Rather, fill your portfolio with companies that have a proven track record of success. 
Via InvestorPlace
News headline image
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach' ↗
Goldman Sachs urges investors to diversify geographically due to high concentration in US tech stocks, with Japan, healthcare, and European GRANOLAS highlighted as promising markets. 
Via Benzinga
News headline image
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise ↗
Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth. 
Via InvestorPlace
News headline image
GSK's Withdrawn Multiple Myeloma Drug Shows Encouraging Combination Therapy Data In Second Late-Stage Study ↗
GSK's DREAMM-8 trial reveals positive interim results for Blenrep combo in relapsed multiple myeloma. Improved progression-free survival and overall survival trend observed. 
Via Benzinga
News headline image
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
From GSK plc
Via Business Wire
News headline image
Injectable HIV Treatment By ViiV Healthcare Outperforms Oral Therapy, Interim Data Shows ↗
Findings from ViiV Healthcare's LATITUDE trial on long-acting HIV treatment. Cabenuva demonstrates superior efficacy in viral load suppression compared to daily oral therapy. Key secondary endpoints... 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Pfizer/GSK-Backed ViiV Healthcare's HIV Drug Associated With Increased Resistance, WHO Report Says ↗
WHO's latest HIV Drug Resistance Report reveals trends in drug resistance. Discover insights on dolutegravir's impact, challenges in HIVDR monitoring, and recommendations for standardized... 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.